PrEP

Top news from across the health care landscape.

Scientists at the Gladstone Institutes have cataloged host proteins that physically bind to HIV proteins, which identify human proteins that the virus can use to infect cells and spread.

The bill is intended to "prevent a health insurance carrier from requiring a covered person to undergo step therapy or to receive prior authorization before receiving HIV infection prevention drugs."

The Undectectable = Untransmittable (U=U) campaign started in early 2016 and has been sharing the message to dismantle the stigma surrounding HIV ever since. More than 970 community partners from 101 countries have come together to clear up the confusion about the science behind U=U.

Research conducted by the National Institute of Minority Health and Health Disparities has found that less than 1 in 4 adolescent men who have sex with men (AMSM) ever get tested for HIV.

The study, called DELIVER: A Phase 3b Safety Study of the Dapivirine Ring and PrEP in Pregnant Women, will complement an ongoing NIH-funded trial of PrEP in adolescents and young women during pregnancy and the first 6 months after birth.

A study funded by the National Institutes of Health (NIH) found that despite similar rates of enrollment into medical care, youth with HIV have much lower rates of viral suppression compared with adults.

Researchers from George Washington University have shown that the human apolipoprotein A-I binding protein (AIBP) is capable of inhibiting HIV replication by targeting lipid rafts and reducing virus-cell fusion.

Decreased PrEP usage was reportedly due to reduced awareness of prevention strategies, and engagement in health-promoting behaviors.

Top news from across the health care landscape.

A study found that an injection of neutralizing antibodies is associated with enhanced T cell response that specifically recognizes HIV.

The mechanism behind HIV resistance affects the ability of integrase strand transfer inhibitors to bind and block the HIV enzyme integrase.

Top news of the day from across the health care landscape.

Robust data show the efficacy of tenofovir disoproxil fumarate with emtricitabine for pre-exposure prophylaxis in all priority populations with a risk for HIV.

Opioid agonist therapy (OAT) must be widely disseminated and increased in Ukraine in order to optimize HIV prevention and treatment goals, according to a recent study published in The Lancet.

Antiretroviral therapy may not be entirely effective in restoring the immune protection resulting from viral infections or childhood vaccines received prior to becoming HIV-positive.

The findings support the inclusion of these patient populations in ICI-based clinical trials and treatment.

Hospitalization offers unique opportunities to engage out-of-care individuals with the ultimate goal of improving their HIV outcomes and reducing health disparities.

The app takes the authoritative, evidence-based 2015 World Health Organization pre-exposure prophylaxis guidelines and adapts for a mobile device.

Top news of the day from across the health care landscape.

The loss of immunity, also referred to as “HIV-associated immune amnesia,” could be related to why people with HIV who are on ART still have shorter lives on average than people without HIV, the study noted.

Dosing based around the frequency of sexual activity provides adequate protection for men vulnerable to HIV infection.

Study shows a high burden of sexually transmitted infections among both individuals starting and persistently using PrEP.

Among eligible MSM, PrEP use is associated with lower levels of HIV anxiety, a mental health benefit that could be incorporated into initiatives that aim to increase uptake.

Through the Ready, Set, PrEP program, qualified patients from across the United States can access PrEP medication for the prevention of HIV, for free.